Our mission is to redefine cancer treatment with therapeutics designed to act precisely at the tumor site for enhanced clinical outcomes and minimal side effects.
Leveraging decades of material science, pharmacology, and cancer biology, PanTher’s innovative approach is truly differentiated from current technologies. By packaging the therapeutics in customized form factors, we can deliver the full dose to the tumoral area and release it locally at high concentrations over an extended period of time. In short, we put all the drug where it is needed.
Targeted, sustained treatments directly at the tumor site
Our platform is widely applicable to many cancer and non-cancer treatments and our name reflects this philosophy.
PanTher was founded in 2016 to develop technology invented in the labs at Massachusetts Institute of Technology (MIT) and Harvard Medical School.
- Proof Of Concept data
- Company spun out with Seed Round
- Scale up manufacturing to clinically relevant prototype
- IND-enabling study demonstrating efficacy, safety, and deployment to the site in clinical settings
- Closed successful Series A
- Initiation of first clinical trial
PanTher’s skilled management team offers years of experience in oncology, biomedical implantable therapeutics, regulatory affairs, and entrepreneurship. Our diverse set of expertise is the foundation of our success.
Elazer Edelman, MD, PhD
Meg Lashof-Sullivan, PhD
Director of R&D
Director of Business Operations
Chris Johnson, PhD
Clinical Operation Support
Corporate Finance Advisor and Board Observer
Board of Directors
Catalyst Health Ventures
Manish Bhandari, MD, E-MBA
Angel Physicians Fund
Maria Palasis, PhD
Chief Executive Officer,
Clinical Advisory Board
Thomas E. Clancy, MD, FACS
Dana-Farber Cancer Institute
Jason Fleming, MD, FACS
Moffitt Cancer Center
Timothy B. Gardner, MD
Dartmouth-Hitchcock Medical Center
Theodore Hong, MD
Massachusetts General Hospital